Could Nutritional Supplements and Cannabis Compounds Modify Multiple Sclerosis?
A comprehensive review found that cannabis constituents and "endocannabinoid-enhancing" compounds could complement MS pharmacotherapy by combining anti-spastic and analgesic effects with potential anti-inflammatory and neuroprotective properties.
Quick Facts
What This Study Found
This extensive review examined nutritional and natural compounds as potential disease-modifying agents for multiple sclerosis. Among many compounds reviewed (vitamin D, fatty acids, probiotics, green tea, curcumin), cannabis constituents stood out for their dual role.
Cannabis compounds and "endocannabinoid-enhancing" nutraceuticals like FAAH inhibitors could provide both symptom relief (spasticity, pain) and disease modification through anti-inflammatory, immune-modifying, and antioxidant mechanisms. Many also inhibit pro-inflammatory NF-kB signaling and stabilize the blood-brain barrier.
The review concluded that while nutraceuticals alone would not solve MS therapeutic challenges, they could support pharmacological interventions or reveal novel drug structures.
Key Numbers
Compounds reviewed: vitamin D, fatty acids, probiotics, cannabis constituents, green tea (EGCG), curcumin, sulforaphane, FAAH inhibitors; mechanisms: NF-kB inhibition, TLR modulation, blood-brain barrier stabilization
How They Did This
Comprehensive review of nutritional and natural compounds with potential disease-modifying activity in MS, including evidence from experimental autoimmune encephalomyelitis models and clinical studies.
Why This Research Matters
MS patients increasingly seek complementary approaches. This review provides an evidence-based assessment of which natural compounds, including cannabis-derived ones, have biological plausibility for disease modification rather than just symptom relief.
The Bigger Picture
The concept of "disease-modifying nutraceuticals" bridges the gap between pharmaceutical treatments and lifestyle interventions for MS. Cannabis compounds fit uniquely into this space because they address both symptoms and underlying mechanisms.
What This Study Doesn't Tell Us
Review covers many compounds with widely varying evidence levels. Most evidence from animal models. Nutraceutical dosing, bioavailability, and quality control are poorly standardized. Interactions with MS medications not well studied.
Questions This Raises
- ?Can nutraceuticals meaningfully supplement MS medications?
- ?What is the optimal combination of natural compounds for MS support?
- ?Should neurologists routinely discuss nutraceutical options with MS patients?
Trust & Context
- Key Stat:
- Cannabis compounds offer dual symptom relief and disease modification potential
- Evidence Grade:
- Extensive review of a wide range of compounds with varying evidence quality, primarily from preclinical studies.
- Study Age:
- Published in 2015. Research on complementary approaches for MS has continued to expand.
- Original Title:
- "Disease modifying nutricals" for multiple sclerosis.
- Published In:
- Pharmacology & therapeutics, 148, 85-113 (2015)
- Authors:
- Schmitz, Katja, Barthelmes, Julia, Stolz, Leonie, Beyer, Susanne, Diehl, Olaf, Tegeder, Irmgard
- Database ID:
- RTHC-01057
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can supplements help with MS?
This review found biological plausibility for several compounds including cannabis constituents, vitamin D, omega-3 fatty acids, and others. However, most evidence was preclinical, and the review emphasized these would complement, not replace, standard treatments.
How do cannabis compounds potentially modify MS?
Beyond symptom relief (spasticity, pain), cannabis compounds and FAAH inhibitors show anti-inflammatory effects, inhibit pro-inflammatory signaling (NF-kB), and may stabilize the blood-brain barrier, all mechanisms relevant to MS progression.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01057APA
Schmitz, Katja; Barthelmes, Julia; Stolz, Leonie; Beyer, Susanne; Diehl, Olaf; Tegeder, Irmgard. (2015). "Disease modifying nutricals" for multiple sclerosis.. Pharmacology & therapeutics, 148, 85-113. https://doi.org/10.1016/j.pharmthera.2014.11.015
MLA
Schmitz, Katja, et al. ""Disease modifying nutricals" for multiple sclerosis.." Pharmacology & therapeutics, 2015. https://doi.org/10.1016/j.pharmthera.2014.11.015
RethinkTHC
RethinkTHC Research Database. ""Disease modifying nutricals" for multiple sclerosis." RTHC-01057. Retrieved from https://rethinkthc.com/research/schmitz-2015-disease-modifying-nutricals-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.